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Supplemental Testing Is Still Required in Australia for Samples Positive
for Neisseria gonorrhoeae by Nucleic Acid Detection Tests
The introduction and widespread application of nucleic acid
detection tests (NADT) for Neisseria gonorrhoeae (i.e., gono-
cocci [GC]) in Australia has enhanced diagnostic capacity and
public health control of gonococcal disease. However, the well-
recognized problems with the use and interpretation of GC
NADT in the difficult and widely varying conditions in Austra-
lia led to a formal request for a specially convened expert
reference group (ERG) to develop guidelines relevant to these
different situations (9). We therefore noted with some concern
conclusions by Lowe et al. (4) suggesting that supplemental
testing for diagnosis of gonorrhea using GC NADT is not
required in Australia when initial testing is by the Gen-Probe
APTIMA Combo 2 (ACT) assay. This assertion contradicts
the recommendations contained in the national consensus
guidelines that were based on a review of the published liter-
ature and the extensive experience obtained over many years in
the diverse test conditions experienced here. The ERG guide-
lines are consistent with another recent review of GC NADT
testing in Australia (11) and the current National Pathology
Accreditation Advisory Council of Australia (NPAAC) guide-
lines (7). The latter supersedes advice contained in the earlier
NPAAC (6) guidelines on which Lowe et al. (4) relied.
There were a number of important factors that were subject
to formal consideration by the Australian ERG seemingly ig-
nored by Lowe et al. (4). First, this ERG (9) pointed to prob-
lems with GC NADT sensitivity that may result from the ca-
pacity of Neisseria gonorrhoeae to repeatedly recombine/alter
its genome through acquisition or loss of genetic sequences.
These alterations result in gain or loss of important character-
istics not only for NADT-based diagnosis but also for culture-
based analyses (3, 8). These subpopulations may vary quite
substantially as a proportion of the total gonococcal population
in different patient subgroups and over time and place (3, 5).
The test numbers mentioned by Lowe et al. (4) suggest that
their study was limited to a sample obtained over approxi-
mately 1 month only, which is insufficient to properly assess any
GC NADT.
Second, the Australian guidelines (9) also emphasized that
cross-reactions with non-gonococcal Neisseria strains remains a
significant limitation of GC NADT and that specificity may
also vary depending on the patient population. Lowe et al. (4)
mention that the AC2 “does not cross-react with other Neis-
seria spp.” To our knowledge, this has not been extensively
investigated in Australia or elsewhere. Hence, the high clinical
specificity of the AC2 observed by Lowe et al. (4) may not
necessarily reflect the performance of the AC2 in other patient
populations, either within or outside Australia. Additionally,
the numbers of assays positive for GC were very low (n  39),
not all four GC NADT were used in all instances introducing
a bias into the “resolved” data, and the population (not spe-
cifically defined) was seemingly a low-prevalence group, fur-
ther compromising the assessment.
Third, experience in Australia has shown us that commercial
GC NADT satisfying existing FDA standards and the earlier
NPAAC guidelines (6) but using limited prerelease evaluation
have had to be subsequently withdrawn from use in Australia
(9). Some “in-house” assays (5) were similarly withdrawn after
more extensive and complete “in-use” appraisals revealed sub-
stantial deficiencies in performance. The relatively small num-
ber of samples examined by Lowe et al. (4) would not reliably
detect these problems.
Also in an Australian context, Lowe et al. relied on a cppB-
based supplemental assay as their final “confirmatory” test (4),
despite the fact that the use of this assay as both a screening
and supplemental assay has been associated with false-negative
and false-positive results both in Australia and elsewhere (1, 3,
9, 10).
It is important that GC NADT is subjected to rigorous,
extensive, and continuing evaluation before being endorsed as
being suitable for use as a single definitive diagnostic test. It is
our view that Lowe et al. (4) failed to satisfy the principles and
details required for proper appraisal of this GC NADT, par-
ticularly in an Australian context. Data such as those presented
may be relevant to some situations and do contribute to the
wider appraisal that we recommend. However, an incomplete
evaluation performed at one geographic location at one time
point on small numbers of positive cases is essentially mean-
ingless if it is to be used, as implied by Lowe et al., as a basis
for universal test validation for a particular GC NADT.
In the opinion of both the Australian ERG (9) and other
national bodies (7), a modification of the Centers for Disease
Prevention and Control approach (2) that includes supplemen-
tal testing provides a reasonable and pragmatic basis for reli-
able reporting of results of GC NADT in Australian condi-
tions. It was also the considered opinion of the ERG (9) that
the available local data on AC2 assays were to date incomplete
and that total reliance on manufacturers’ data to remedy this
deficiency may be misplaced. The additional information sup-
plied by Lowe et al. (4) does not alter these views.
The Public Health Laboratory Network of Australia and the Na-
tional Neisseria Network of Australia endorsed the opinions expressed
above.
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Authors’ Reply
We appreciate the comments provided by Lum et al. (re-
ferred to as “the authors” throughout this reply) regarding our
publication. The authors raise points which we believe warrant
reply.
The authors appropriately highlight the well-known difficul-
ties encountered in the confirmation of positive screening with
Neisseria gonorrhoeae nucleic acid amplification tests (GC
NAAT) (14, 17). They highlight the cppB gene assay and three
others developed or being evaluated by members of the expert
reference group (ERG) (porA pseudogene, opa, and a cytosine
DNA methyltransferase gene assay [1, 3, 14–16]). We support
the authors comments referring to the problematic genetic
variation associated with these and other potential targets and
the impact on diagnostic testing. However, none of these
genes are targets for the APTIMA Combo 2 (AC2) or
APTIMA Neisseria gonorrhoeae (AGC) assays (Gen-Probe In-
corporated, San Diego, CA).
The AC2 assay has been in the marketplace since 2001 and
extensively tested on four continents with comparable results.
We are unaware of published reports of either assay (AC2 or
AGC) cross-reacting with non-gonococcal isolates as yet.
Peer-reviewed studies in the public domain since 2003 (2,
4–7, 11) have detailed the diagnostic performance of the AC2
assay, including in low-prevalence populations (7), and have
also highlighted that both the AC2 and AGC assays target
different regions of the 16S rRNA gene (5). Comparison with
earlier work (8) clearly contradicts the authors’ assertion (14)
that the AGC assay does not demonstrate major divergences
from “an earlier version of the same assay.” Gen-Probe, in fact,
did not have an amplified GC assay on the market before the
AC2 assay. The AC2 assay was FDA cleared in August 2001
for the semiautomated systems, while the AGC was FDA
cleared in March 2005 for the same systems (Gen-Probe In-
corporated, San Diego, CA). At the time of our evaluation, we
used the analyte-specific reagent version of the product.
Good laboratory practice requires that each laboratory eval-
uate the performance and appropriate use of any test for the
population of patients to which it provides services. The aim of
our study was to compare the AC2 assay to our then existing
testing technology (Roche AMPLICOR CT/NG for detection
of Chlamydia trachomatis and GC with confirmation of GC
positives by cppB gene detection) in our referral population.
Our criteria for the determination of “true positive” results
were based on published contemporary Australian and Amer-
ican guidelines (9, 12), i.e., repeat testing of all positives using
another set of primers directed at a different target sequence.
The National Pathology Accreditation Advisory Council of
Australia guidelines (13) were in draft form at the time of
submission. The relevant sections quoted by the authors are
identical to the guidelines published in 2000 (12).
We are unclear how the authors concluded that our study
was conducted over a 1-month period with samples from one
geographic location. Our sampling of specimens was con-
ducted from April to September 2004. QML Pathology pro-
vides private referral outpatient and inpatient diagnostic ser-
vices across the state of Queensland, Australia (population,
approximately 4 million), comprising 22.5% of the Australian
land mass. We perform over 75,000 tests for Chlamydia tra-
chomatis and Neisseria gonorrhoeae per annum. Our state-wide
catchment area includes low- and high-prevalence populations,
including indigenous and nonindigenous Australians. We
therefore believe that the selection timeframe and the diversity
of our population catchment area to be at least reasonable and
certainly negates the points raised in this regard by the authors.
Additionally, the authors inaccurately quote the number of
true positives with GC (45; not 39, as stated by them). We
believe our sample size and number of positive GC specimens
(n  45) equates with a previous Australian-based study by
some members of the ERG (15).
In our view, the diagnostic sensitivity, specificity, and pre-
dictive values were sufficient to pose a question regarding the
need for confirmatory GC testing (10). We are not the first to
pose this question. Similar results and conclusions from a com-
parable study in a low-prevalence population have been pub-
lished (7). Importantly, we did not state in our publication that
confirmatory testing of GC NAAT be abandoned in Australia
or elsewhere.
While Lum et al. raise some valid points concerning the
overall issue of GC NAAT in Australia, their criticisms and
supporting evidence have not dealt specifically with the re-
ported performance of the APTIMA GC NAAT assay in our
population and dismissed the evidence from other overseas
studies. This is unfortunate given the position of the authors;
however, on the basis of the arguments they present here, we
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see no justification for changing our view that the APTIMA
GC NAAT assay does have a place in the laboratory diagnosis
of Neisseria gonorrhoeae infection in our population.
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